NCT00006240View on ClinicalTrials.gov

Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2000

Study Completion Date

August 31, 2001

Conditions
Leukemia
Interventions
BIOLOGICAL

sargramostim

DRUG

dexamethasone

DRUG

oral sodium phenylbutyrate

Trial Locations (4)

10029

Mount Sinai Medical Center, NY, New York

20892

National Heart, Lung, and Blood Institute, Bethesda

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

15213-3489

University of Pittsburgh Cancer Institute, Pittsburgh

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00006240 - Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter